From: A national physician survey on prescribing syringes as an HIV prevention measure
Respondents (N = 588) | Non-Respondents (N = 1971) |
Chi-square p-value | |
---|---|---|---|
Gender | |||
Female | 29.8% (175) | 24.9% (491) | 0.01 |
Age (mean ± std) | |||
Age: | 49.3 ± 11.2 | 51.1 ± 12.4 | 0.0009 |
Specialty | |||
Primary | 81.3% (478) | 85.6% (1687) | 0.0001 |
Emergency Medicine | 12.9% (76) | 8.3% (164) | |
Specialist | 5.8% (34) | 6.1% (120) | |
Region | |||
Northeast | 26.2% (152) | 24.7% (487) | 0.75 |
South | 26.7% (155) | 28.8% (568) | |
Midwest | 23.2% (135) | 23.1% (455) | |
West | 23.9% (139) | 23.4% (461) | |
Homestate syringe law | |||
Strict Prohibition | 27.0% (149) | 30.4% (599) | 0.12 |
Access Intermediate | 40.1% (221) | 40.6% (800) | |
Open access syringe sales | 32.8% (181) | 29.0% (572) | |
Syringe Exchange Program | |||
Legal SEP | 52.8% (309) | 50.0% (986) | 0.12 |
SEP w/o claim to legal | 27.2% (159) | 26.1% (514) | |
No SEP operating | 20.0% (117) | 23.9% (471) |